2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3018 A study of glucocorticoids combined with intravenous immunoglobulin and romiplostim N01 in the treatment of newly diagnosed severe immune thrombocytopenia (ITP)

Hu Yu, MD, Ming Hou2, Han Yue, MD,PhD3, Lei Zhang, MD4, Sheng-Jin Fan5, Guolin Yuan6, Huili Cai7
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Qilu Hospital of Shandong University, Jinan, China
3 The First Affiliated Hospital of Soochow University, Suzhou, China
4 Chinese Academy of Medical Sciences (CAMS) Blood Disease Hospital, Tianjin, China
5 The First Hospital of Harbin Medical University, Harbin, China
6 Xiangyang Central Hospital, Xiangyang, China
7 Yichang Central Hospital, Yichang, China

Title: A Study of Glucocorticoids Combined with Intravenous Immunoglobulin and Romiplostim N01 in the Treatment of Newly Diagnosed Severe Immune Thrombocytopenia (ITP)

Yu Hu, PhD1, Ming Hou, PhD2,Yue Han, PhD3,Lei Zhang, PhD4, Shengjin Fan, PhD5, Guolin Yuan, PhD6, Huili Cai, PhD7


 1Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 2Qilu Hospital, Shandong University, Jinan, China 3The First Affiliated Hospital of Soochow University, Suzhou, China 4Chinese Academy of Medical Sciences (CAMS) Blood Diseases Hospital, Tianjin, China 5The First Hospital of Harbin Medical University, Harbin, China 6Xiangyang Central Hospital, Xiangyang, China 7Yichang Central Hospital, Yichang, China

Background: Early treatment with thrombopoietin receptor agonists (TPO-RAs) has demonstrated significant efficacy in patients with immune thrombocytopenia (ITP), reducing the need for glucocorticoids and preventing the progression of newly diagnosed or persistent ITP to chronic disease. Most patients receiving TPO-RA therapy achieve an initial response within 1–2 weeks, and 70%–80% attain long-term remission. Romiplostim N01, a TPO-RA, binds to c-MPL on megakaryocytes and their progenitors, inducing homodimerization and activating the JAK-STAT and MAPK-ERK signaling pathways, thereby promoting megakaryocyte growth, development, and proliferation, leading to increased platelet counts. This study aims to evaluate the efficacy and safety of glucocorticoids combined with intravenous immunoglobulin (IVIG) and romiplostim N01 in patients with newly diagnosed severe ITP.

 

Study Design: This multicenter, prospective, single-arm study was conducted across seven hospitals in China. A total of 31 eligible patients with newly diagnosed severe ITP were enrolled after screening. Patient demographics included a mean age of 56.9 ± 15.7 years (range: 25–76 years), with 21 males (67.7%) and 10 females (32.3%). Baseline ECOG performance status scores were 0 in 8 patients (25.8%), 1 in 21 patients (67.7%), 2 in 1 patient (3.2%), and 3 in 1 patient (3.2%).

All patients received a combination regimen of glucocorticoids, IVIG, and romiplostim N01. The dosing schedule was as follows: methylprednisolone at 0.8 mg/kg/day, administered orally or intravenously for up to one month; IVIG at 400 mg/kg/day, administered intravenously for 3–5 consecutive days; and romiplostim N01 at a starting dose of 1 µg/kg, administered subcutaneously.

The primary endpoint was the overall response rate (ORR) at 30 days. Secondary endpoints included: the early response rate (RR) at Day 8, defined as the proportion of patients with a platelet count between 30 × 10?/L and 100 × 10?/L, at least a twofold increase from baseline, and absence of bleeding symptoms; the early complete response rate (CRR) at Day 8, defined as the proportion of patients with a platelet count ≥ 100 × 10?/L and absence of bleeding symptoms; time to response, defined as the time from treatment initiation to a platelet count ≥ 30 × 10?/L; and adverse events during the treatment period.

 

Results: Among patients with newly diagnosed severe ITP treated with glucocorticoids, IVIG, and romiplostim N01, the ORR at 30 days was 96.4%, and the CRR was 82.1%. Early responses with romiplostim N01 were observed as follows: at Day 4, the ORR was 71.0% (22/31), and the CRR was 58.1% (18/31); at Day 8, the ORR was 93.6% (29/31), and the CRR was 67.7% (21/31). At Day 30 follow-up, the ORR was 96.4%, and the CRR was 82.1% (23/28). At Day 58, the ORR was 90.5% (19/21) and the CRR was 71.4% (15/21). At Day 86, the ORR was 81.8% (18/22), and the CRR was 72.7% (16/22). In terms of safety, grade 1–2 adverse events occurred in 12.9% (4/31) of patients, including abdominal pain, hyperlipidemia, and elevated bilirubin, of which two cases had resolved. Grade ≥3 adverse events occurred in 3.2% (1/31), presenting as liver function abnormalities, which were manageable. No treatment discontinuations due to adverse events were reported.

 

Conclusion:

The combination of glucocorticoids, IVIG, and romiplostim N01 demonstrates robust clinical efficacy and a manageable safety profile in patients with newly diagnosed severe ITP. This regimen represents a promising potential first-line standard treatment for this patient population.

Hu Yu, MD: No relevant conflicts of interest to declare.